Results 91 to 100 of about 772 (113)

Efficacy and safety of estetrol (15 mg)/drospirenone (3 mg) combination in a cyclic regimen for the treatment of primary and secondary dysmenorrhea: a multicenter, placebo-controlled, double-blind, randomized study

Yutaka Osuga, Takao Kobayashi, Akihiro Hirakawa, Toshiaki Takayanagi, Masayoshi Nogami, Kyaw Tayzar, Takayuki Mochiyama, Masashi Hirayama, Jean‐Michel Foidart, Tasuku Harada   +9 more
openalex   +1 more source

Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1

Herjan J.T. Coelingh Bennink, Erik P.M. Roos, R. Jeroen A. van Moorselaar, Harm H.E. van Melick, Diederik Meindert Somford, Ton A. Roeleveld, Tjard D. de Haan, Yacov Reisman, Iman J. Schultz, Jan Krijgh, Frans M.J. Debruyne   +10 more
openalex   +1 more source

Characteristics of uterine bleeding associated with an oral contraceptive containing drospirenone in combination with estetrol: A multicenter observational study

Irina V. Kuznetsova, Liudmila V. Evsyukova   +1 more
openalex   +2 more sources

Insights on estetrol, the native estrogen: from contraception to hormone replacement therapy

Christian Battipaglia, Alessandro David Genazzani, Rossella Elena Nappi, Antonio La Marca   +3 more
openalex   +2 more sources

Ovulation inhibition by estetrol in an in vivo model

Contraception, 2008
Background: Currently, the synthetic steroid ethinylestradiol (EE) is the preferred estrogen in combined oral contraceptives. The aim of the present study was to evaluate the effectiveness of the natural steroid estetrol (E-4) as an ovulation inhibitor ...
Herjan J T Coelingh Bennink
exaly   +4 more sources

Estetrol: A New Choice for Contraception

Journal of Clinical Medicine, 2021
Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver. Recent research has demonstrated that it is a potent, orally bioavailable, natural selective estrogen receptor modulator; it has a moderate affinity for both ...
Franca Fruzzetti, Tommaso Simoncini, Maria Magdalena Montt Guevara   +2 more
exaly   +2 more sources

Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results

Contraception, 2021
ObjectiveTo assess efficacy, cycle control, and safety of an oral contraceptive containing estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg.Study designWomen aged 16 to 50 years with a body mass index ≤35 kg/m2 enrolled in this multicenter, open-label ...
Mitchell Creinin, Jean-Michel Foidart, Carolyn Westhoff   +2 more
exaly   +2 more sources

Estetrol/Drospirenone safety in a population with cardiovascular risk factors [PDF]

Contraception
ObjectivesTo evaluate cardiovascular safety outcomes in estetrol 15mg/drospirenone 3mg users with cardiovascular risk factors.Study designWe performed a secondary analysis of two open-label contraceptive phase-3 trials that enrolled participants 16 to 50
Mitchell Creinin, Kristina Gemzell-Danielsson, Archie Kubba   +2 more
exaly   +2 more sources

Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol [PDF]

Contraception, 2017
peer reviewedObjective The effects of estetrol (E4), a natural fetal estrogen, combined with drospirenone (DRSP) were evaluated on plasma levels of sex hormone-binding globulin (SHBG), angiotensinogen and 12 hemostasis markers.
Jean-Michel Foidart, Christine Klipping   +1 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone

Contraception, 2021
Jean-Michel Foidart, Christine Klipping, Íngrid Duijkers   +2 more
exaly